Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mengyu Hou

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Clinical and Translational Science|November 13, 2024
Evaluation of drug-drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjectsJingcheng Chen, Jingxuan Wu, Nini Guo, et al.
Clinical and Translational Science|June 25, 2026
Drug Interactions of Vebreltinib, a Novel Type I c-Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy ParticipantsJingcheng Chen, Jingxuan Wu, Yuqin Song, et al.
The Journal of Infection|October 28, 2023
Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adultsZhili Jin, Jingxuan Wu, Ying Wang, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Clinical and Translational Science|November 13, 2024
Evaluation of drug-drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjectsJingcheng Chen, Jingxuan Wu, Nini Guo, et al.
Clinical and Translational Science|June 25, 2026
Drug Interactions of Vebreltinib, a Novel Type I c-Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy ParticipantsJingcheng Chen, Jingxuan Wu, Yuqin Song, et al.
The Journal of Infection|October 28, 2023
Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adultsZhili Jin, Jingxuan Wu, Ying Wang, et al.
Pageof 2